Cftr Trikafta denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Trikafta as Not FDA-Approved — and Why That Is Almost Certainly Wrong

A "not FDA-approved" denial from UnitedHealthcare (UHC) for Trikafta (elexacaftor/tezacaftor/ivacaftor) is one of the clearest factual errors a health plan can make. Trikafta has received FDA approval for cystic fibrosis (CF). If this denial has been issued for your claim, the most probable explanations are a coding error on the claim, an outdated coverage policy that has not been updated to reflect the approval, or a mismatch between the mutation profile documented on the claim and the mutation class covered by the FDA label. All of these are correctable.

## Why This Denial Happens

Automated adjudication systems compare drug codes and diagnosis codes against fixed policy tables. If the policy table has not been refreshed, or if the claim lacks a diagnosis code that maps to the FDA-approved indication, a "not approved" flag can be generated in error. In rare cases, the denial reflects a prescribing use that is genuinely off-label — but for patients whose CFTR mutation falls within the labeled indication, that argument does not apply.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 or applicable state law, file a formal appeal within the deadline on the denial letter. Demand in writing that UHC identify the specific basis for the "not FDA-approved" determination and produce the coverage policy relied upon, including its effective date.
• External review (ACA §2719): Disputes about FDA approval status are reviewable by an independent external reviewer. File for external review within approximately four months of the final internal denial. The external reviewer will consult the FDA approval record directly.
• Expedited review: If supply interruption would seriously jeopardize health, request the 72-hour expedited track.
• State insurance commissioner: If UHC's policy is demonstrably out of date with respect to a current FDA approval, a concurrent complaint to the state department of insurance is a strong parallel action.

## Documentation to Gather

1. FDA approval record — the current FDA-approved prescribing label and the original approval letter for Trikafta. These are publicly available from FDA.gov. 2. Mutation confirmation — genetic testing records confirming the patient's CFTR mutation(s) and a prescriber statement that the mutation falls within the FDA-approved indication. 3. Claim coding review — ask your specialty pharmacy or billing team to verify that the drug and diagnosis codes on the submitted claim correctly reflect an on-label use. 4. UHC policy effective date — request and review the specific coverage policy UHC cited; if it predates the FDA approval, that discrepancy is the centerpiece of your appeal. 5. Prescriber letter — CF specialist attestation that the prescribed use is within the FDA-approved indication, referencing the label.

## Criteria-Mapping Structure

Obtain UHC's coverage policy and the FDA prescribing label. Build a direct rebuttal:

| Basis for "Not FDA-Approved" Denial | Evidence Rebutting It | |---|---| | Claim that Trikafta lacks FDA approval | FDA approval letter and current prescribing label | | Off-label use concern (if raised) | Mutation documentation confirming on-label use | | Policy effective date vs. FDA approval date | Direct date comparison showing policy is outdated |

This denial type, when addressed with FDA documentation and mutation confirmation, is among the most reliably reversed at internal review.